Skip to main navigation
Menu
Main navigation
Advocacy
Issue Overview
#Rx4StateSavings
#4GRxANTED
#MarkupMadness
State Advocacy
GDUFA/BsUFA User Fees
Biosimilars Council
Action Center
Our Impact
Join
About Us
Generic Quality
About AAM
Our Team
Our Members
Generic Medicines
Biosimilars Council
Meet Our Board
Social Commitment
Careers
Contact Us
Stories
Events
Access! 2025
GRx+Biosims 2024
Resources
All Resources
Drug Shortages White Paper
2023 Savings Report
Biosimilars Patient Resource Center
Biosimilar Research & Studies
Press Releases
Blog
Founders Blogs
Amicus Briefs
Take Action
Search
Close
Breadcrumb
Association for Accessible Medicines
Resources
Resources
Share
Find up-to-date information on generics and biosimilars
Filter Resources
Issues
Biosimilar User Fee Act (BsUFA)
Biosimilars
Complex Generics
Drug Approval Process (GDUFA)
Drug Prices
Drug Shortages
Generic Drug Labeling
Generic Supply Chain
IP Issues
Low Income Subsidies (LIS in Part D)
Medicaid
Medicare
NAFTA
Patent Reform
Patient Stories
Pharmaceutical Waste Take Back
Preventing Drug Abuse
Quality
REMS/Sample Acquisition Remedies
State Initiatives
Tariffs
Trade
Transparency
User Fees
Resource Type
Blog
Amicus Brief
Press Release
Infographic
Video
Report
Fact Sheet
Presentation
Fact Sheet
Jan 8, 2018
| Erica Klinger
Oppose Washington Senate Bill 5995
Report
Jan 4, 2018
| Erica Klinger
7 Policy Solutions
Fact Sheet
Dec 22, 2017
| Carrie Hartgen
Oppose New Hampshire House Bill 1780
Blog
Dec 15, 2017
| Erica Klinger
House Subcommittee Examines the Drug Supply Chain
Blog
Dec 14, 2017
| Rachel Schwartz
The Right People in the Room to Prevent Opioid Abuse on Campus
Press Release
Dec 11, 2017
| Rachel Schwartz
AAM Calls for FTC Action to Ensure U.S. Supply of Generic Drugs for Patients
Amicus Brief
Dec 1, 2017
| Erica Klinger
MYLAN PHARMACEUTICALS INC., TEVA PHARMACEUTICALS USA, INC., and AKORN INC., Petitioners v. ALLERGAN, INC., Patent Owner
Fact Sheet
Dec 1, 2017
| Erica Klinger
AAM Amicus Brief - Mylan vs. Allergan
Blog
Nov 28, 2017
| Erica Klinger
Seeking Asylum for Its Patents on Tribal Lands: The Latest Brand-Name Drug Company Strategy to Preserve Monopoly Pricing
Blog
Nov 21, 2017
| Erica Klinger
#EndtheShenanigans, Says Gottlieb
Blog
Nov 20, 2017
| Erica Klinger
Recap: AAM’s FallTech Conference 2017
Blog
Nov 16, 2017
| Erica Klinger
How the Medicaid Generics Penalty Jeopardizes Patient Access
Load More
Advocacy
Issue Overview
#Rx4StateSavings
#4GRxANTED
#MarkupMadness
State Advocacy
GDUFA/BsUFA User Fees
Biosimilars Council
Action Center
Our Impact
Join
About Us
Generic Quality
About AAM
Our Team
Our Members
Generic Medicines
Biosimilars Council
Meet Our Board
Social Commitment
Careers
Contact Us
Stories
Events
Access! 2025
GRx+Biosims 2024
Resources
All Resources
Drug Shortages White Paper
2023 Savings Report
Biosimilars Patient Resource Center
Biosimilar Research & Studies
Press Releases
Blog
Founders Blogs
Amicus Briefs
Take Action